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What is known about this subject?
The main method for treating basal cell carcinoma is surgical excision with a healthy safety margins.
What new information is offered in this case study?
The treatment with Vismodegib can be used as preoperative therapy for advanced, primarily difficult to remove basal cell carcinoma.
What are the implications for research, policy, or practice?
The treatment with Vismodegib allows surgeons to perform radical excisions in smaller volume with better cosmetic result.
Background
Basal cell carcinoma is the most common, malignant, neoplastic disease on the skin and in the organism in general. 1 It accounts for 70 per cent of the keratinocyte cancers. 1, 2 Its frequency is around two per cent of the general population, depending on the latitude and the population age. Most affected are areas of the body, exposed to direct sunlight. The tumour has very slow growth and rarely metastasis. 3, 4 Its clinical presentation varies from a nodular formation to a slowly healing ulcer. The main treatment method is a radical surgical excision of the carcinoma. Other surgical and nonsurgical methods are also used.
Here we will present our clinical case of a patient with advanced, primarily difficult to remove basal cell carcinoma on the upper lip, treated with peroral intake of Vismodegib 150mg, followed by a surgical excision.
Case details
We present a 54-year-old patient with no accompanying diseases. Around four years ago he noticed a whitish swelling with dilated blood vessels on top of it on his upper lip, left side. The swelling's size was around 0.5/0.5cm. It started growing, and around the end of May 2017, it turned into an ulcer with crusts and elevated, uneven edges, sized around 2.5/2.5cm ( Figure 1 ).
Figure 1: Tumour view before the oral treatment
After this change, a consult with a dermatologist was requested, who biopsied the lesion. The histology result was a basal cell carcinoma with multifocal cornification. Disease was staged as T3N0M0 ( Figure 2 ).
Figure 2: Histological specimen from the biopsy of the primary tumour
The regional oncology committee, due to the impossibility of a radical excision and bad cosmetic effect in case of a possible primary surgical treatment, decided, in according to the country's medical norms, for a presurgical peroral therapy with Erivedge (Vismodegib) 150mg, one capsule daily for four months.
During the drug therapy patient showed no signs of side effects. During the physical examination at the moment of hospitalization after the end of peroral treatment it was visible that the ulcer with elevated edges had disappeared, and at that spot there was a whitish, dense plaque, size around 1/1cm, looking like a cicatrix ( Figure 3 ).
Figure 3: View of the affected site four months after the oral treatment
Due to Bulgaria's norms for good medical practice in the complex treatment of the basal cell carcinoma and the patient's cancerophobia, a decision for surgical treatment was made. Under local anaesthesia with 1 per cent Sol. Lidocaini was performed a local wide excision (2mm. safety margin) ( Figure 4 ).
Figure 4: Result after local excision of the affected site
A plastic reconstruction of the upper lip was performed by advanced the musculocutaneous flap after cutting the tissues immediately up to the lateral border of the left nose wing ( Figure 5 ).
Figure 5: Result after the surgical treatment
The result of the histopathological examination was: skin and subcutaneous tissue with chronic productive inflammatory process, formation of granulomas with giant cell reaction and lack of tumour cells ( Figure 6 ). radiotherapy, external exposure to arsenic, immunosuppressive conditions. 6 The tumour growth is slow and rarely there are distant metastases, but in case of incorrect and delayed treatment leads to the formation of massive progressing ulcers, destroying underlying tissues and disfiguring the affected areas. 3, 4 The clinical presentation of a basal cell carcinoma is usually elevated, shiny part of the skin with pearly nodules and dilated blood vessels above it or an ulcer with elevated edges, often covered with crust and bleeding when touched. Clinical forms are: nodular, cystic, cicatricial, infiltrative, micronodular, superficial, pigmented and fibroepithelioma of Pinkus. 7, 8 Diagnose is confirmed after the histopathological examination of a biopsy material from the suspected lesion.
Main method for the treatment of a basal cell carcinoma is its radical surgical excision, but if the tumour is very small, Mohs surgery is preferred. 6 The latter was developed in 1938 by the surgeon Frederic Mohs and consists of surgical removal of layers of the tumour skin lesion in a very tight margin, with constant histopathological examination of the layers for tumour invasion, until complete radicality is achieved. 9, 10 Other methods for local treatment include cryodestruction, laser therapy and local chemotherapy. Drugs for systemic chemotherapy, immunotherapy and target therapy are also used. 11 In elderly patients with local advanced, disfiguring or metastatic basal cell carcinoma, which cannot be surgically removed, the target therapy with peroral capsules Vismodegib 150mg under trade name Erivedge 150mg, one capsule daily for four months, has very good effects. The drug is a small molecule systemic inhibitor of the Hedgehog (Hh) intracellular signalling pathway, which leads to the activation of many genes, participating in the proliferation, survivability and differentiation of cells. Its usage has been permitted in Europe since 12th of July 2013, after which it has been included in a multicentre study of its effectiveness and safety. 1232 elderly patients were included, with locally advanced or metastatic basal cell carcinoma of the skin, and most of them had previously underwent another method for local (excision, radiotherapy) or systemic (chemotherapy) treatment. Complete response was achieved in 4.8 per cent of patients with metastatic and 33.4 per cent of those with locally advanced basal cell carcinoma. Partial response was achieved in 32.1 per cent of patients with metastatic and 35.1 per cent of those with locally advanced basal cell carcinoma. The response was determined after macroscopic and biopsy evaluation of the affected area and observation of the regress of distant metastases through multiple imaging scans. 12 In that study the result of the preoperative drug use is not separately discussed, and there is scarce medical data about it in literature.
The presented case is about a proven large and ulcerated basal cell carcinoma of the left part of the upper lift, which, upon diagnosing, is unfit for radical surgical treatment, due to its size and location.
Therefore, peroral target therapy with Vismodegib was started, aiming to reduce the tumour size and make it operable. The result was achieved in the end of the 4 month course of the Vismodegib therapy and a surgical treatment was performed. The operation resulted in good cosmetic effect and lack of residual cancer cells, as can be seen from the histological result described above.
Conclusion
Basal-cell carcinoma of the skin is a socially significant disease due to its high frequency among the human population. Often patients seek medical help too late, when the primary radical surgical treatment is no longer a possibility. In those cases the modern preoperative therapy with Erivedge (Vismodegib) 150mg is highly beneficial to them -it leads to the reduction of the tumour size and even disappearance of tumour cells from the affected area. This by itself allows surgeons to perform radical excisions in smaller volume with better cosmetic result.
